• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TSSC5的体细胞突变,TSSC5是位于人类染色体11p15.5的一个新的印记基因。

Somatic mutation of TSSC5, a novel imprinted gene from human chromosome 11p15.5.

作者信息

Lee M P, Reeves C, Schmitt A, Su K, Connors T D, Hu R J, Brandenburg S, Lee M J, Miller G, Feinberg A P

机构信息

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

出版信息

Cancer Res. 1998 Sep 15;58(18):4155-9.

PMID:9751628
Abstract

We previously reported the isolation of a 2.5 Mb tumor-suppressing subchromosomal transferable fragment (STF) from 11p15.5 and the identification of nine known genes and four novel genes within this STF. We now report the isolation of a fifth novel cDNA, tumor-suppressing STF cDNA 5, designated TSSC5, located within the STF. TSSC5 encodes a predicted protein of 424 amino acids. Sequence analysis suggests that TSSC5 is a membrane protein with 10 transmembrane segments, and it is located between two imprinted genes, p57KIP2 and TSSC3. Northern blot hybridization revealed a 1.6-kb transcript in multiple adult tissues and in fetal liver and kidney, consistent with a potential role in embryonal tumors. We also found that TSSC5 is imprinted with preferential expression from the maternal chromosome. Reverse transcription-PCR analysis of TSSC5 revealed frequent occurrence of aberrant RNA splicing, which deleted exons 4, 5, and 6 in Wilms' tumors. Mutational analysis of TSSC5 by direct DNA sequencing of exons revealed a base substitution of G1120A in a Wilms' tumor, matched normal kidney, and the patient's mother, changed Arg at codon 309 to Gln. The G1120A substitution thus represents either a rare polymorphism or a tumor-predisposing mutation, because the mutant allele was of maternal origin and preferentially expressed in the patient's tissue. A second base substitution, C892T, was found in a lung cancer, changing Ser at codon 233 to Phe. This substitution was absent from the matched normal tissue and thus represented a somatic mutation. We also found loss of heterozygosity in the lung cancer, suggesting that TSSC5 may be a conventional tumor suppressor gene in the adult human lung and an imprinted tumor suppressor gene in the fetal kidney.

摘要

我们之前报道了从11p15.5分离出一个2.5 Mb的肿瘤抑制亚染色体可转移片段(STF),并鉴定出该STF内的9个已知基因和4个新基因。我们现在报告分离出第五个新的cDNA,即肿瘤抑制STF cDNA 5,命名为TSSC5,位于该STF内。TSSC5编码一个预测的由424个氨基酸组成的蛋白质。序列分析表明,TSSC5是一种具有10个跨膜区段的膜蛋白,它位于两个印记基因p57KIP2和TSSC3之间。Northern印迹杂交显示在多种成人组织以及胎儿肝脏和肾脏中有一个1.6 kb的转录本,这与它在胚胎肿瘤中的潜在作用一致。我们还发现TSSC5是印记基因,母源染色体优先表达。对TSSC5的逆转录 - PCR分析显示,在肾母细胞瘤中频繁出现异常RNA剪接,导致外显子4、5和6缺失。通过对外显子直接DNA测序对TSSC5进行突变分析,发现在一个肾母细胞瘤、配对的正常肾脏以及患者母亲中存在G1120A的碱基替换,使密码子309处的精氨酸变为谷氨酰胺。因此,G1120A替换要么代表一种罕见的多态性,要么代表一种肿瘤易感突变,因为突变等位基因来自母源且在患者组织中优先表达。在一个肺癌中发现了第二个碱基替换C892T,使密码子233处的丝氨酸变为苯丙氨酸。该替换在配对的正常组织中不存在,因此代表一个体细胞突变。我们还在肺癌中发现了杂合性缺失,提示TSSC5可能是成人人类肺癌中的一个传统肿瘤抑制基因,以及胎儿肾脏中的一个印记肿瘤抑制基因。

相似文献

1
Somatic mutation of TSSC5, a novel imprinted gene from human chromosome 11p15.5.TSSC5的体细胞突变,TSSC5是位于人类染色体11p15.5的一个新的印记基因。
Cancer Res. 1998 Sep 15;58(18):4155-9.
2
Two novel genes in the center of the 11p15 imprinted domain escape genomic imprinting.位于11p15印记区域中心的两个新基因逃避了基因组印记。
Hum Mol Genet. 1999 Apr;8(4):683-90. doi: 10.1093/hmg/8.4.683.
3
A 2.5-Mb transcript map of a tumor-suppressing subchromosomal transferable fragment from 11p15.5, and isolation and sequence analysis of three novel genes.
Genomics. 1997 Nov 15;46(1):9-17. doi: 10.1006/geno.1997.4981.
4
Tumor suppressor candidate TSSC5 is regulated by UbcH6 and a novel ubiquitin ligase RING105.肿瘤抑制候选基因TSSC5受UbcH6和一种新型泛素连接酶RING105调控。
Oncogene. 2006 Mar 2;25(9):1330-9. doi: 10.1038/sj.onc.1209167.
5
p57K1P2 is expressed in Wilms' tumor with LOH of 11p15.5.p57K1P2在11p15.5杂合性缺失的肾母细胞瘤中表达。
Genes Chromosomes Cancer. 1996 Sep;17(1):56-9. doi: 10.1002/(SICI)1098-2264(199609)17:1<56::AID-GCC8>3.0.CO;2-1.
6
Multiple genetic abnormalities of 11p15 in Wilms' tumor.肾母细胞瘤中11p15的多种基因异常。
Med Pediatr Oncol. 1996 Nov;27(5):484-9. doi: 10.1002/(SICI)1096-911X(199611)27:5<484::AID-MPO16>3.0.CO;2-A.
7
Divergently transcribed overlapping genes expressed in liver and kidney and located in the 11p15.5 imprinted domain.在肝脏和肾脏中表达且位于11p15.5印记区域的反向转录重叠基因。
Genomics. 1998 Apr 1;49(1):38-51. doi: 10.1006/geno.1998.5221.
8
Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.细胞周期蛋白依赖性激酶抑制剂p57KIP2在软组织肉瘤和肾母细胞瘤中的作用
Cancer Res. 1996 Mar 15;56(6):1219-21.
9
SKCG-1: a new candidate growth regulatory gene at chromosome 11q23.2 in human sporadic Wilms tumours.
Br J Cancer. 2006 May 22;94(10):1524-32. doi: 10.1038/sj.bjc.6603090.
10
Genomic organization of the human p57KIP2 gene and its analysis in the G401 Wilms' tumor assay.人类p57KIP2基因的基因组结构及其在G401肾母细胞瘤检测中的分析。
Cancer Res. 1996 Mar 15;56(6):1214-8.

引用本文的文献

1
Analysis of SLC genes alternative splicing identifies the SLC7A6 RI isoform as a therapeutic target for colorectal cancer.对溶质载体(SLC)基因可变剪接的分析确定溶质载体家族7成员6(SLC7A6)RI亚型为结直肠癌的治疗靶点。
Cancer Sci. 2025 Jan;116(1):233-247. doi: 10.1111/cas.16351. Epub 2024 Oct 15.
2
Multiomics Analysis of the PHLDA Gene Family in Different Cancers and Their Clinical Prognostic Value.不同癌症中PHLDA基因家族的多组学分析及其临床预后价值
Curr Issues Mol Biol. 2024 May 30;46(6):5488-5510. doi: 10.3390/cimb46060328.
3
A Syndrome of Variable Allergy, Short Stature, and Fatty Liver.
一种具有可变过敏、身材矮小和脂肪肝的综合征。
Front Genet. 2022 Jan 24;12:784135. doi: 10.3389/fgene.2021.784135. eCollection 2021.
4
Weak sharing of genetic association signals in three lung cancer subtypes: evidence at the SNP, gene, regulation, and pathway levels.三种肺癌亚型中遗传关联信号的微弱共享:在 SNP、基因、调控和通路水平的证据。
Genome Med. 2018 Feb 27;10(1):16. doi: 10.1186/s13073-018-0522-9.
5
Characterization of SLC22A18 as a tumor suppressor and novel biomarker in colorectal cancer.SLC22A18作为结直肠癌肿瘤抑制因子和新型生物标志物的特征分析。
Oncotarget. 2015 Sep 22;6(28):25368-80. doi: 10.18632/oncotarget.4681.
6
In vitro and in vivo radiosensitization of human glioma U251 cells induced by upregulated expression of SLC22A18.SLC22A18表达上调诱导人胶质瘤U251细胞的体外和体内放射增敏作用
Cancer Gene Ther. 2014 Mar;21(3):103-9. doi: 10.1038/cgt.2014.4. Epub 2014 Jan 31.
7
Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.SLC22A18 蛋白表达在接受替莫唑胺治疗的胶质母细胞瘤患者中的预测价值。
J Transl Med. 2013 Mar 20;11:69. doi: 10.1186/1479-5876-11-69.
8
Elevated expression of solute carrier family 22 member 18 increases the sensitivity of U251 glioma cells to BCNU.溶质载体家族22成员18的表达升高增加了U251胶质瘤细胞对卡莫司汀的敏感性。
Oncol Lett. 2011 Nov;2(6):1139-1142. doi: 10.3892/ol.2011.371. Epub 2011 Aug 4.
9
[Expression and its clinical significance of SLC22A18 in non-small cell lung cancer].SLC22A18在非小细胞肺癌中的表达及其临床意义
Zhongguo Fei Ai Za Zhi. 2012 Jan;15(1):17-20. doi: 10.3779/j.issn.1009-3419.2012.01.04.
10
Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma.SLC22A18 的启动子甲基化和下调与人类胶质瘤的发生和发展有关。
J Transl Med. 2011 Sep 21;9:156. doi: 10.1186/1479-5876-9-156.